The biopharma industry was certainly not immune to the turbulence brought about by the COVID-19 pandemic. The pandemic disrupted — and in some...
Read moreCell Therapies
Gene and Cell Therapy Developers Are Getting Creative to Keep Programs on Track During the Pandemic
Jeanette Young, senior consultant for analytical services at BioTechLogic talks with Tonia Becker, Life Sciences Editor, Macon Raine As it became clear that the COVID-19...
Lessons and Insights into the Korean Biopharmaceutical Market During the COVID-19 Pandemic
Tonia Becker, Life Sciences Editor, Macon Raine talks with BioTechLogic’s Dr. Eileen Choi How is the COVID-19 pandemic affecting the global biopharmaceutical market?...
FDA Seeking to Enhance Manufacturing of Cell Therapy and Gene Therapy Products
More consistent and reliable production cell therapy and gene therapy processes are critical for advancing innovative treatments. While cell therapy and gene therapy...
Comprehensive Regenerative Medicine Policy Framework Announced by FDA
On November 16, 2017 the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products,...
Therapeutic Gene Editing: An American Society of Gene & Cell Therapy White Paper
Interested in learning more about gene editing and its therapeutic applications? Download a new white paper from the American Society of Gene & Cell Therapy (ASGCT). The...